26530-77-8

Basic information

• Product Name: 9,10-dimethoxy-13-(prop-2-en-1-yl)-5,13a-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline
• CAS NO: 26530-77-8
• Molecular Formula: C₂₃H₂₃NO₄
• Molecular Weight: 377.433
• Mol File: 26530-77-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 624.2°C at 760 mmHg
• Flash Point: 185.7°C
• Density: 1.29g/cm³
• Vapor Pressure: 1.69E-15mmHg at 25°C
• Refractive Index: 1.653
• CAS DataBase Reference: 9,10-dimethoxy-13-(prop-2-en-1-yl)-5,13a-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 9,10-dimethoxy-13-(prop-2-en-1-yl)-5,13a-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline(26530-77-8)
• EPA Substance Registry System: 9,10-dimethoxy-13-(prop-2-en-1-yl)-5,13a-dihydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline(26530-77-8)

Safety Data

• Hazardous Substances Data: 26530-77-8(Hazardous Substances Data)

Upstream product

• 633-65-8 berberine chloride 
• 39024-13-0 acetoneberberine 
• 106-95-6 allyl bromide 

Relevant articles and documents

Synthesis and antitubercular activity of berberine derivatives

The isoquinoline alkaloid berberine (1) was isolated from the roots of Berberis aristata and its new, 13-benzyl (3-6), 13-allyl (7, 8), 8-(2-oxopropyl) (2), and 9-hydroxy (9) derivatives have been synthesized under mild conditions with good yield. The structures of the new derivatives were confirmed by spectroscopic (UV, IR, NMR, and MS) analysis. The antitubercular activity of the derivatives against Mycobacterium tuberculosis H37Rv was studied (microdilution assay) and compared with rifampicin as standard drug. The results demonstrated that the 4-chlorobenzyl (4), 2,4-dichlorobenzyl (5), 4-fluorobenzyl (6), and 3″,3″-dimethylallyl (8) derivatives exhibited (MIC, 4-8 μg/mL) 2-4 fold more activity than berberine (MIC, 16 μg/mL), which is probably due to the 13-benzyl and allyl substitution in the molecule.

NOVEL ISOQUINOLINE DERIVATIVES

The invention provides novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein, compositions including the compounds and methods of preparing and using the compounds.